U.S. SaMD & FDA's New Rules: Pure Global on The Hidden Mandate.

In this episode of MedTech Global Insights, we dissect the FDA's unexpected new mandatory cybersecurity rules for connected medical devices. What was once guidance is now a critical requirement for market access, demanding continuous post-market surveillance and proactive threat modeling that has left many manufacturers scrambling to adapt. We explore the immediate consequences for startups, mid-size companies, and large enterprises, who now face significant unplanned costs and logistical challenges. A European company, for example, believed its FDA submission for an already EU-approved device was straightforward. Now, they are forced to halt their U.S. launch to build a completely new, five-year cybersecurity plan from scratch, jeopardizing investor timelines and market entry. Key Takeaways: - Why is the FDA’s new guidance more than just a simple document update? - What are the three most critical components of the new mandatory surveillance plan? - How does this rule change the budget for a medical device startup overnight? - What steps must companies with existing products on the market take immediately? - How can you turn this new regulatory burden into a competitive advantage? - What are the key differences between the FDA’s new rules and EU MDR cybersecurity requirements? - How can AI-powered tools help automate the new threat modeling and documentation demands? For more information, contact us at [email protected], visit https://pureglobal.com/, or explore our FREE AI tools and medical device database at https://pureglobal.ai/.